Concepts (78)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Amyotrophic Lateral Sclerosis | 11 | 2026 | 517 | 1.380 |
Why?
|
| Chlordiazepoxide | 1 | 2017 | 4 | 0.530 |
Why?
|
| Hypoxia, Brain | 1 | 2017 | 10 | 0.530 |
Why?
|
| Chorea | 1 | 2017 | 10 | 0.530 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 2 | 2006 | 13 | 0.460 |
Why?
|
| Saccharomyces cerevisiae Proteins | 2 | 2006 | 451 | 0.340 |
Why?
|
| Double-Blind Method | 8 | 2026 | 747 | 0.340 |
Why?
|
| Taurochenodeoxycholic Acid | 2 | 2020 | 3 | 0.330 |
Why?
|
| Phenylbutyrates | 2 | 2020 | 6 | 0.330 |
Why?
|
| Brain | 1 | 2017 | 1672 | 0.280 |
Why?
|
| Neurofilament Proteins | 1 | 2024 | 26 | 0.210 |
Why?
|
| Disease Progression | 2 | 2026 | 1229 | 0.200 |
Why?
|
| Nerve Growth Factors | 2 | 2022 | 28 | 0.200 |
Why?
|
| Enzyme Inhibitors | 1 | 2025 | 372 | 0.190 |
Why?
|
| Biomarkers | 2 | 2024 | 1502 | 0.160 |
Why?
|
| Neuroprotective Agents | 1 | 2020 | 80 | 0.160 |
Why?
|
| Mutation | 3 | 2020 | 2675 | 0.160 |
Why?
|
| Saccharomyces cerevisiae | 1 | 2005 | 573 | 0.150 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2020 | 148 | 0.150 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2019 | 40 | 0.150 |
Why?
|
| C9orf72 Protein | 1 | 2019 | 115 | 0.140 |
Why?
|
| Globus Pallidus | 1 | 2017 | 26 | 0.130 |
Why?
|
| Basal Ganglia | 1 | 2017 | 34 | 0.130 |
Why?
|
| Male | 10 | 2026 | 31403 | 0.130 |
Why?
|
| Middle Aged | 9 | 2026 | 18498 | 0.120 |
Why?
|
| Treatment Outcome | 5 | 2026 | 5834 | 0.120 |
Why?
|
| Hypoxia | 1 | 2017 | 121 | 0.120 |
Why?
|
| Brain Injuries | 1 | 2017 | 141 | 0.120 |
Why?
|
| Mutagenesis, Site-Directed | 2 | 2006 | 252 | 0.110 |
Why?
|
| Aged | 7 | 2026 | 15145 | 0.110 |
Why?
|
| Adult | 6 | 2025 | 17575 | 0.100 |
Why?
|
| MicroRNAs | 1 | 2020 | 714 | 0.100 |
Why?
|
| Humans | 13 | 2026 | 65830 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2013 | 17 | 0.100 |
Why?
|
| Anterior Eye Segment | 1 | 2013 | 6 | 0.100 |
Why?
|
| Eye Abnormalities | 1 | 2013 | 21 | 0.100 |
Why?
|
| Chromosome Deletion | 1 | 2013 | 42 | 0.100 |
Why?
|
| Leukoencephalopathies | 1 | 2013 | 25 | 0.100 |
Why?
|
| Amino Acid Sequence | 2 | 2006 | 1590 | 0.090 |
Why?
|
| Molecular Sequence Data | 2 | 2006 | 1980 | 0.090 |
Why?
|
| Female | 9 | 2026 | 34420 | 0.090 |
Why?
|
| Transplantation, Autologous | 2 | 2022 | 128 | 0.080 |
Why?
|
| Vital Capacity | 2 | 2021 | 123 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2017 | 2324 | 0.080 |
Why?
|
| Protein Subunits | 1 | 2006 | 169 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 1 | 2006 | 672 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2005 | 899 | 0.050 |
Why?
|
| Time | 1 | 2020 | 30 | 0.040 |
Why?
|
| Intention to Treat Analysis | 1 | 2020 | 21 | 0.040 |
Why?
|
| Meningoencephalitis | 1 | 2020 | 9 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2020 | 39 | 0.040 |
Why?
|
| Injections, Spinal | 1 | 2020 | 44 | 0.040 |
Why?
|
| Protein Binding | 1 | 2005 | 1638 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2020 | 167 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 2020 | 122 | 0.040 |
Why?
|
| Young Adult | 2 | 2020 | 4882 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 174 | 0.040 |
Why?
|
| DNA Repeat Expansion | 1 | 2019 | 59 | 0.040 |
Why?
|
| Spinal Cord | 1 | 2020 | 210 | 0.040 |
Why?
|
| Heterozygote | 1 | 2019 | 175 | 0.040 |
Why?
|
| Gene Silencing | 1 | 2020 | 439 | 0.030 |
Why?
|
| Pandemics | 1 | 2021 | 691 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1291 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 1569 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2019 | 2500 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2020 | 930 | 0.020 |
Why?
|
| Eye Diseases, Hereditary | 1 | 2013 | 3 | 0.020 |
Why?
|
| Receptor, Notch3 | 1 | 2013 | 10 | 0.020 |
Why?
|
| High-Temperature Requirement A Serine Peptidase 1 | 1 | 2013 | 10 | 0.020 |
Why?
|
| Dependovirus | 1 | 2020 | 760 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2020 | 852 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2013 | 132 | 0.020 |
Why?
|
| Receptors, Notch | 1 | 2013 | 110 | 0.020 |
Why?
|
| Serine Endopeptidases | 1 | 2013 | 125 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2019 | 3339 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2020 | 5681 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 6367 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2019 | 6955 | 0.020 |
Why?
|